Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAtrium Therapeutics, Inc. Common Stock

Atrium Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
7.96 USD -0.27 ( 3.28%)
Last update at 2026-11-11T21:00:00Z
VOLUME
130118
Market Cap
172.60M

Momentum Score

…

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.94
Low
8.26
High
52 Week Price Range
9.62
Low
16.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Atrium Therapeutics, Inc. (NASDAQ: RNA) is limited; available filings and disclosures characterize it as an early-stage biopharmaceutical company developing therapeutic candidates for serious or rare diseases. Long-term growth may depend on successful clinical development, regulatory approvals, and strategic partnerships, and investors may find potential upside if the company advances programs that address unmet medical needs.

Material risks include clinical and regulatory failure, substantial funding and dilution risk from ongoing capital needs, an unproven operating history with no predictable revenues, and limited public disclosure that increases uncertainty for investors.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.23
Dividend Yield
-
Revenue TTM
35.84M
Revenue Per Share
2.10
Gross Profit TTM
-20.20M
Debt / Equity
0.02
ROE
-43.98%
Net Debt
-266.33M
ROCE
-32.48%
Diluted EPS TTM
-5.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -76.83M -322.30M -212.22M -174.00M -118.01M
Net income -76.68M -322.30M -212.22M -169.08M -117.37M
Selling general administrative 41.68M 86.24M 54.19M 37.73M 26.20M
Selling and marketing expenses - - 2.10M - -
Gross profit 18.62M 10.90M 7.46M 9.22M 9.33M
Reconciled depreciation 0.32M 2.78M 1.87M 1.39M 0.64M
Ebit -76.83M -378.94M -235.60M -180.30M -118.69M
Ebitda -76.50M -376.16M -233.50M -178.91M -118.05M
Depreciation and amortization 0.32M 2.78M 2.10M 1.39M 0.64M
Operating income -76.81M -378.94M -235.60M -178.91M -118.05M
Other operating expenses 95.43M 389.83M 245.16M 188.14M 127.38M
Interest expense - - - 5.69M 0.64M
Tax provision -0.14M 11.91M 0.00M - -
Interest income - 56.88M 20.34M 4.97M 0.10M
Net interest income - 56.88M 20.34M 4.97M 0.10M
Income tax expense -0.14M - 1.93M -4.92M -0.64M
Total revenue 18.62M 10.90M 9.56M 9.22M 9.33M
Total operating expenses 95.43M 389.83M 243.06M 188.14M 127.38M
Cost of revenue 4.15M 2.78M 2.10M - -
Total other income expense net -0.01M 56.63M 23.38M 4.92M 0.04M
Net income from continuing ops -76.68M -322.30M -202.25M -174.00M -118.01M
Net income applicable to common shares - - - -174.00M -118.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 278.35M 1563.89M 628.55M 638.80M 427.58M
Other current assets 2.85M 12.57M 14.05M 12.21M 5.60M
Total liab 71.07M 138.94M 127.79M 60.73M 46.15M
Total stockholder equity 207.29M 1424.96M 500.76M 578.08M 381.43M
Other current liab 12.09M 64.73M 39.87M 39.12M 23.02M
Common stock 0.02M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.02M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1577.70M -893.07M -570.76M -358.54M -184.55M
Other liab - - - 1.24M 6.53M
Other assets - - 0.00M 0.85M 0.85M
Cash 270.00M 219.87M 185.08M 340.40M 405.54M
Total current liabilities 41.80M 98.02M 80.68M 51.91M 29.66M
Current deferred revenue 21.64M 20.99M 28.36M 5.04M 4.86M
Net debt -266.33M -213.07M -175.23M -329.71M -395.58M
Short term debt 3.67M 3.84M 3.64M 3.10M 1.77M
Short long term debt total 3.67M 6.80M 9.85M 10.69M 9.96M
Other stockholder equity 207.27M 2315.11M 1071.39M 939.31M 566.16M
Property plant equipment - - - 15.01M 15.59M
Total current assets 272.85M 1542.29M 611.31M 622.94M 411.14M
Net tangible assets - - - 578.08M 381.43M
Short term investments 1314.35M 1281.63M 410.27M 270.33M 85.09M
Net receivables 12.44M 28.22M 1.91M 2.10M 0.90M
Accounts payable 4.40M 8.46M 8.81M 4.64M 14.09M
Accumulated other comprehensive income 2.56M 2.90M 0.12M -2.70M -0.19M
Non currrent assets other 84.97M 3.32M 0.30M 0.85M 0.85M
Non current assets total 5.51M 21.61M 17.25M 15.86M 16.44M
Capital lease obligations 3.67M 6.80M 9.85M 7.58M 11.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -854.20M -188.88M -189.96M -78.78M
Change to liabilities - - - 13.20M 1.60M
Total cashflows from investing activities -1.45M -854.20M -130.07M -189.96M -82.52M
Total cash from financing activities 42.57M 1192.36M 93.86M 346.17M 176.32M
Change to operating activities - - - -3.38M 3.74M
Net income -49.50M -322.30M -212.22M -174.00M -118.01M
Change in cash 162.65M 37.29M -155.27M 19.95M -1.01M
Begin period cash flow 222.66M 185.38M 340.65M 320.70M 321.71M
End period cash flow 385.31M 222.66M 185.38M 340.65M 320.70M
Total cash from operating activities -41.13M -300.87M -119.06M -136.27M -94.81M
Issuance of capital stock - 1000.55M 303.62M 344.78M 185.94M
Depreciation 0.32M 2.78M 2.10M 1.39M 0.64M
Other cashflows from investing activities -4.07M - - - -
Dividends paid - - - - 0.00M
Change to account receivables 0.00M 0.75M 1.39M - -
Other cashflows from financing activities 42.57M 191.81M 33.32M 1.39M -9.62M
Change to netincome - - - 26.52M 17.22M
Capital expenditures 1.45M 7.07M 4.23M 2.82M 3.74M
Change in working capital -0.20M -14.56M 61.13M 9.82M 5.34M
Stock based compensation 7.68M 51.36M 38.22M 27.14M 17.06M
Other non cash items 0.71M -18.15M -8.30M -0.61M 0.16M
Free cash flow -42.57M -307.94M -123.29M -139.09M -98.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RNA
Atrium Therapeutics, Inc. Common Stock		 -0.27
3.28%		 7.96 - - 4.82 0.80 491.01 -5.72
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Atrium Therapeutics, Inc. Common Stock

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

10578 Science Center Drive, San Diego, CA, United States, 92121

619 876 0700

https://atriumtherapeutics.com

511

Name Title Year Born
Dr. Troy Edward Wilson J.D., Ph.D. Co-Founder & Chairman 1969
Ms. Sarah Boyce Pres, CEO & Director 1972
Mr. Michael F. MacLean Chief Financial & Bus. Officer 1966
Dr. W. Michael Flanagan Ph.D. Chief Technical Officer 1962
Dr. Arthur A. Levin Ph.D. Chief Scientific Officer 1954
Prof. Mark E. Davis Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s NA
Dr. Frank McCormick Ph.D. Scientific Founder & Member of Scientific Advisory Board 1950
Ms. Kathleen Gallagher Sr. VP of Corp. Communications & Investor Relations NA
Dr. John W. Wallen III VP of Intellectual Property, Gen. Counsel & Sec. 1958
Ms. Teresa McCarthy Chief HR Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…